PMID- 34983504
OWN - NLM
STAT- MEDLINE
DCOM- 20220228
LR  - 20221207
IS  - 1475-2840 (Electronic)
IS  - 1475-2840 (Linking)
VI  - 21
IP  - 1
DP  - 2022 Jan 4
TI  - Association between glycemic control and risk of venous thromboembolism in 
      diabetic patients: a nested case-control study.
PG  - 2
LID - 10.1186/s12933-021-01432-1 [doi]
LID - 2
AB  - BACKGROUND: Previous studies suggested an elevated risk of venous thromboembolism 
      (VTE) among patients with type 2 diabetes mellitus (T2DM), with a possible sex 
      difference. The impact of glycemic control on the risk of VTE is unclear. Our 
      objective was to analyze the association between glycemic control and the risk of 
      unprovoked (idiopathic) VTE in men and women with T2DM. METHODS: We conducted a 
      nested case-control analysis (1:4 matching) within a cohort of patients with 
      incident T2DM between 1995 and 2019 using data from the CPRD GOLD. We excluded 
      patients with known risk factors for VTE prior to onset of DM. Cases were T2DM 
      patients with an unprovoked treated VTE. The exposure of interest was glycemic 
      control measured as HbA1c levels. We conducted conditional logistic regression 
      analyses adjusted for several confounders. RESULTS: We identified 2'653 VTE cases 
      and 10'612 controls (53.1% females). We found no association between the HbA1c 
      level and the risk of VTE in our analyses. However, when the most recent HbA1c 
      value was recorded within 90 days before the index date, women with HbA1c 
      levels > 7.0% had a 36-55% increased relative risk of VTE when compared to women 
      with HbA1c > 6.5-7.0%. CONCLUSIONS: Our study raises the possibility that female 
      T2DM patients with HbA1c levels > 7% may have a slightly higher risk for 
      unprovoked VTE compared to women with HbA1c levels > 6.5-7.0%. This increase may 
      not be causal and may reflect differences in life style or other characteristics. 
      We observed no effect of glycemic control on the risk of VTE in men.
CI  - (c) 2021. The Author(s).
FAU - R Charlier, Sarah H
AU  - R Charlier SH
AD  - Basel Pharmacoepidemiology Unit, Division of Clinical Pharmacy and Epidemiology, 
      Department of Pharmaceutical Sciences, University of Basel, Spitalstrasse 26, 
      4056, Basel, Switzerland.
AD  - Hospital Pharmacy, University Hospital Basel, Basel, Switzerland.
FAU - Meier, Christian
AU  - Meier C
AD  - Division of Endocrinology, Diabetes & Metabolism, University Hospital Basel, 
      Basel, Switzerland.
FAU - Jick, Susan S
AU  - Jick SS
AD  - Boston Collaborative Drug Surveillance Program, Lexington, USA.
AD  - School of Public Health, Boston University, Boston University School of Medicine, 
      Lexington, USA.
FAU - Meier, Christoph R
AU  - Meier CR
AD  - Basel Pharmacoepidemiology Unit, Division of Clinical Pharmacy and Epidemiology, 
      Department of Pharmaceutical Sciences, University of Basel, Spitalstrasse 26, 
      4056, Basel, Switzerland. christoph.meier@unibas.ch.
AD  - Hospital Pharmacy, University Hospital Basel, Basel, Switzerland. 
      christoph.meier@unibas.ch.
AD  - Boston Collaborative Drug Surveillance Program, Lexington, USA. 
      christoph.meier@unibas.ch.
FAU - Becker, Claudia
AU  - Becker C
AD  - Basel Pharmacoepidemiology Unit, Division of Clinical Pharmacy and Epidemiology, 
      Department of Pharmaceutical Sciences, University of Basel, Spitalstrasse 26, 
      4056, Basel, Switzerland.
AD  - Hospital Pharmacy, University Hospital Basel, Basel, Switzerland.
LA  - eng
PT  - Journal Article
PT  - Observational Study
DEP - 20220104
PL  - England
TA  - Cardiovasc Diabetol
JT  - Cardiovascular diabetology
JID - 101147637
RN  - 0 (Biomarkers)
RN  - 0 (Blood Glucose)
RN  - 0 (Glycated Hemoglobin A)
RN  - 0 (hemoglobin A1c protein, human)
SB  - IM
MH  - Aged
MH  - Aged, 80 and over
MH  - Biomarkers/blood
MH  - Blood Glucose/*metabolism
MH  - Case-Control Studies
MH  - Diabetes Mellitus, Type 2/blood/diagnosis/epidemiology/*therapy
MH  - Female
MH  - Glycated Hemoglobin/metabolism
MH  - *Glycemic Control
MH  - Humans
MH  - Incidence
MH  - Male
MH  - Middle Aged
MH  - Risk Assessment
MH  - Risk Factors
MH  - Sex Factors
MH  - Time Factors
MH  - Treatment Outcome
MH  - United Kingdom/epidemiology
MH  - Venous Thromboembolism/diagnostic imaging/*epidemiology
PMC - PMC8729078
OTO - NOTNLM
OT  - Case-control study
OT  - Diabetes mellitus type 2
OT  - Glycemic control
OT  - HbA1c
OT  - Sex
OT  - VTE
OT  - Venous thromboembolism
COIS- We have no conflict of interest to declare, financial or otherwise.
EDAT- 2022/01/06 06:00
MHDA- 2022/03/01 06:00
PMCR- 2022/01/04
CRDT- 2022/01/05 05:38
PHST- 2021/09/10 00:00 [received]
PHST- 2021/12/09 00:00 [accepted]
PHST- 2022/01/05 05:38 [entrez]
PHST- 2022/01/06 06:00 [pubmed]
PHST- 2022/03/01 06:00 [medline]
PHST- 2022/01/04 00:00 [pmc-release]
AID - 10.1186/s12933-021-01432-1 [pii]
AID - 1432 [pii]
AID - 10.1186/s12933-021-01432-1 [doi]
PST - epublish
SO  - Cardiovasc Diabetol. 2022 Jan 4;21(1):2. doi: 10.1186/s12933-021-01432-1.